The Aromotise Inhibitor Exemestane (Aromasin) as a PED for Women ?

The third-generation aromatase inhibitors (AI) Anastrozole (Arimidex), Letrozole (Femara), and Exemestane (Aromasin) ” function” by virtue of blocking the extragonadal conversion of androgens to estrogens and giving rise to an estrogen-depleted environment.

AIs fall into two classes, steroidal Ai’s as represented by Exemestane, which acts as a suicide inhibitor of aromatase, and nonsteroidal including anastrozole and letrozole, which reversibly block aromatase activity

In men, this suppression of Estrogen causes an increase in Testosterone Production * ( the very premise of why we use estrogen suppression in PCT ) however this does not occur in Women so it’s not through this mechanism Exemestane (Aromasin) might be considered as a PED for Women

* 25 mg per day of Exemestane causes a 33{2658607c068490114260e14c260e6ae174f4b10b752c604f4a58b348bf83bb16} increase in Testosterone levels.

Exemestane itself has almost no androgenic effect, however when administered to Humans Exemestane undergoes a complex metabolism the primary metabolite of which is 17-hydroexemestane, which accumulates to a concentration of about 10{2658607c068490114260e14c260e6ae174f4b10b752c604f4a58b348bf83bb16} of its parent compound

and this metabolite of Exemestane is able to interact with the androgen receptor and regulate AR-dependent activities.

Firstly this obviously means that “gen pop” women should consider this fact before using Exemestane or not, but also means this drug becomes of interest to enhanced women with modest objectives.

Now 10{2658607c068490114260e14c260e6ae174f4b10b752c604f4a58b348bf83bb16} might not seem like a lot however consider two things a subpopulation of patients may exist who metabolize exemestane at higher rates, leading to correspondingly higher circulating 17-hydroexemestane levels. For instance, one of three patients administered 800 mg of exemestane, the highest dose to date evaluated in Humans, achieved 17-hydroexemestane plasma levels approximately one-half the level of the parent compound.


we have a study to consider where Exemestane is given at 25mg/day in comparison to Tamoxifen where they measured Bodycomposition changes

In the Exemestane group, FFM showed a constant and significant increase during the study, with percentage changes with respect to baseline values of 3.4{2658607c068490114260e14c260e6ae174f4b10b752c604f4a58b348bf83bb16} and 5.1{2658607c068490114260e14c260e6ae174f4b10b752c604f4a58b348bf83bb16}, respectively, at 12 and 24 months see the image attached.

In contrast, FM showed a weak but significant decrease confirmed at all times of measurement (−2.1{2658607c068490114260e14c260e6ae174f4b10b752c604f4a58b348bf83bb16} and
−2.8{2658607c068490114260e14c260e6ae174f4b10b752c604f4a58b348bf83bb16}, at 12 and 24 months.

The FFM/FMratio progressively increased in the exemestane group over the study period +7.0{2658607c068490114260e14c260e6ae174f4b10b752c604f4a58b348bf83bb16} at month 24

In the two years of the study the women of the Exemestane group had gained an average of 2.2 kg of lean mass with a average loss of fat mass of 0,7 kg.

No significant changes in FFM, FM, or FFM/FM ratio were detected in tamoxifen-treated patients at any time point.

During this time Triglyceride levels in the blood of women in the Exemestane group had fallen, a positive development, but at the same time the Exemestane had increased LDL levels and reduced HDL concentrations, a negative development

Exemestane had increased LDL levels and reduced HDL concentrations.

Now 2.2kg ( 5 pounds ) of Lean Muscle Tissue might not seem like a lot agree, but for Women interested in moderate outcomes Exemestane (Aromasin) becomes one possible drug to consider.

Caution, like ALL PEDs every last one there is the good, the bad and the potentially ugly here.. this post is drawing attention only to the potential of Exemestane as a Bodyrecomposition agentt in Women. It does not consider downside of deployment

Educate yourself

Victor Black